293480.KS
Hana Pharm Co., Ltd. [293480.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
293480.KS Stock Summary
Top 10 Correlated ETFs
293480.KS
Top 10 Correlated Stocks
293480.KS
In the News
293480.KS Financial details
Company Rating
Buy
Market Cap
229.39B
Income
22.33B
Revenue
224.46B
Book val./share
16068.97
Cash/share
356.01
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
10.42
Forward P/E
-
PEG
-12.83
P/S
1.12
P/B
0.9
P/C
37.19
P/FCF
19.11
Quick Ratio
-
Current Ratio
1.71
Debt / Equity
0.1
LT Debt / Equity
0.01
-
-
EPS (TTM)
1.29K
EPS next Y
-
EPS next Q
-
EPS this Y
-8.12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.4%
Revenue last 5Y
6.18%
Revenue Q/Q
3.19%
EPS Q/Q
43.4%
-
-
-
-
SMA20
-3.62%
SMA50
-1.96%
SMA100
-3.55%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
9%
ROC
0.1%
Gross Margin
63%
Oper. Margin
13%
Profit Margin
11%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13170.0-16190.0
52W High
-18.22%
52W Low
+0.53%
RSI
40
Rel Volume
0.99
Avg Volume
21.84K
Volume
21.71K
Perf Week
-0.75%
Perf Month
-2.86%
Perf Quarter
-3.15%
Perf Half Y
-4.61%
-
-
-
-
Beta
0.474651
-
-
Volatility
97.81%, 265.37%
Prev Close
-0.23%
Price
13240
Change
0.15%
293480.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 9.5K | 10.25K | 11.77K | 12.19K | 12.97K | |
| Net income per share | 1.62K | 860.74 | 1.68K | 1.41K | 1.29K | |
| Operating cash flow per share | 1.81K | 900.45 | 1.54K | 1.79K | 1.06K | |
| Free cash flow per share | -115.1 | -90.2 | -548.72 | -282.55 | 215.05 | |
| Cash per share | 5.11K | 4.24K | 3.41K | 1.02K | 356.01 | |
| Book value per share | 12.59K | 13.43K | 15.1K | 15.51K | 16.07K | |
| Tangible book value per share | 12.27K | 12.97K | 14.33K | 14.82K | 15.24K | |
| Share holders equity per share | 12.59K | 13.43K | 15.1K | 15.51K | 16.07K | |
| Interest debt per share | 314.77 | 263.03 | 648.51 | 2.01K | 1.59K | |
| Market cap | 358.87B | 405.03B | 336.19B | 307.93B | 248.77B | |
| Enterprise value | 349.35B | 388.99B | 340.35B | 329.48B | 273.88B | |
| P/E ratio | 12.68 | 27.2 | 12 | 12.67 | 11.14 | |
| Price to sales ratio | 2.16 | 2.28 | 1.71 | 1.46 | 1.11 | |
| POCF ratio | 11.31 | 26 | 13.1 | 9.97 | 13.52 | |
| PFCF ratio | -178.11 | -259.53 | -36.72 | -63 | 66.87 | |
| P/B Ratio | 1.63 | 1.74 | 1.33 | 1.15 | 0.89 | |
| PTB ratio | 1.63 | 1.74 | 1.33 | 1.15 | 0.89 | |
| EV to sales | 2.1 | 2.19 | 1.73 | 1.56 | 1.22 | |
| Enterprise value over EBITDA | 8.8 | 11.69 | 8.16 | 8.48 | 8.12 | |
| EV to operating cash flow | 11.01 | 24.97 | 13.27 | 10.67 | 14.88 | |
| EV to free cash flow | -173.38 | -249.25 | -37.18 | -67.41 | 73.62 | |
| Earnings yield | 0.08 | 0.04 | 0.08 | 0.08 | 0.09 | |
| Free cash flow yield | -0.01 | 0 | -0.03 | -0.02 | 0.01 | |
| Debt to equity | 0.02 | 0.02 | 0.04 | 0.13 | 0.1 | |
| Debt to assets | 0.02 | 0.02 | 0.04 | 0.1 | 0.08 | |
| Net debt to EBITDA | -0.24 | -0.48 | 0.1 | 0.55 | 0.74 | |
| Current ratio | 4.72 | 4.32 | 3.44 | 2.32 | 1.82 | |
| Interest coverage | 604.88 | 609.18 | 796.89 | 53.22 | 25.22 | |
| Income quality | 1.12 | 1.05 | 0.92 | 1.27 | 0.82 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | |
| Payout ratio | 0.16 | 0.49 | 0.29 | 0.36 | 0.4 | |
| Sales general and administrative to revenue | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.06 | |
| Intangibles to total assets | 0.02 | 0.03 | 0.04 | 0.03 | 0.04 | |
| Capex to operating cash flow | -1.06 | -1.1 | -1.36 | -1.16 | -0.8 | |
| Capex to revenue | -0.2 | -0.1 | -0.18 | -0.17 | -0.07 | |
| Capex to depreciation | -8.03 | -3.43 | -6.04 | -5.51 | -1.94 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 21.4K | 16.13K | 23.88K | 22.15K | 21.6K | |
| ROIC | 0.12 | 0.07 | 0.11 | 0.08 | 0.07 | |
| Return on tangible assets | 0.11 | 0.06 | 0.1 | 0.07 | 0.07 | |
| Graham Net | 5.26K | 4.47K | 3.46K | -343.39 | -314.67 | |
| Working capital | 125.23B | 113.56B | 99.61B | 58.82B | 46.29B | |
| Tangible asset value | 214.85B | 224.41B | 239.06B | 256.41B | 263.58B | |
| Net current asset value | 116.19B | 103.6B | 88.86B | 25.96B | 32.02B | |
| Invested capital | 0.02 | 0.02 | 0.04 | 0.13 | 0.1 | |
| Average receivables | 42.84B | 43.07B | 43.23B | 43.65B | 45.31B | |
| Average payables | 6.63B | 6.49B | 6.36B | 7.37B | 7.26B | |
| Average inventory | 24.45B | 28.81B | 35.71B | 41.05B | 44.88B | |
| Days sales outstanding | 93.29 | 89.81 | 79.61 | 76.96 | 75.07 | |
| Days payables outstanding | 45.1 | 34.79 | 37.16 | 36.97 | 28.15 | |
| Days of inventory on hand | 174.77 | 177.24 | 226.45 | 189.84 | 211.08 | |
| Receivables turnover | 3.91 | 4.06 | 4.58 | 4.74 | 4.86 | |
| Payables turnover | 8.09 | 10.49 | 9.82 | 9.87 | 12.97 | |
| Inventory turnover | 2.09 | 2.06 | 1.61 | 1.92 | 1.73 | |
| ROE | 0.13 | 0.06 | 0.11 | 0.09 | 0.08 | |
| Capex per share | -1.93K | -990.64 | -2.09K | -2.07K | -848.78 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.15K | 3.13K | 3.32K | 3.21K | 3.32K | |
| Net income per share | 397.63 | 307.01 | 445.73 | 221.12 | 317.09 | |
| Operating cash flow per share | 494.79 | 294.48 | 299.4 | 124.72 | 345.24 | |
| Free cash flow per share | 385.27 | -331.89 | 369.59 | -16.85 | 208.46 | |
| Cash per share | 1.02K | 626.68 | 458.87 | 446.09 | 356.01 | |
| Book value per share | 15.51K | 15.13K | 15.61K | 15.83K | 16.07K | |
| Tangible book value per share | 14.82K | 14.39K | 14.87K | 15.02K | 15.24K | |
| Share holders equity per share | 15.51K | 15.13K | 15.61K | 15.83K | 16.07K | |
| Interest debt per share | 1.98K | 1.58K | 1.73K | 1.75K | 1.59K | |
| Market cap | 307.93B | 257.24B | 243.4B | 240.98B | 248.77B | |
| Enterprise value | 329.48B | 280.56B | 271.82B | 269.7B | 273.88B | |
| P/E ratio | 11.19 | 12.11 | 7.89 | 15.75 | 11.34 | |
| Price to sales ratio | 5.65 | 4.75 | 4.24 | 4.33 | 4.34 | |
| POCF ratio | 35.97 | 50.5 | 46.99 | 111.69 | 41.65 | |
| PFCF ratio | 46.2 | -44.8 | 38.07 | -826.63 | 68.98 | |
| P/B Ratio | 1.15 | 0.98 | 0.9 | 0.88 | 0.89 | |
| PTB ratio | 1.15 | 0.98 | 0.9 | 0.88 | 0.89 | |
| EV to sales | 6.05 | 5.19 | 4.74 | 4.85 | 4.77 | |
| Enterprise value over EBITDA | 31.84 | 8.25 | 7.5 | 7.86 | 35.4 | |
| EV to operating cash flow | 38.49 | 55.07 | 52.48 | 125 | 45.86 | |
| EV to free cash flow | 49.43 | -48.86 | 42.51 | -925.13 | 75.95 | |
| Earnings yield | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Free cash flow yield | 0.02 | -0.02 | 0.03 | 0 | 0.01 | |
| Debt to equity | 0.13 | 0.1 | 0.11 | 0.11 | 0.1 | |
| Debt to assets | 0.1 | 0.08 | 0.09 | 0.09 | 0.08 | |
| Net debt to EBITDA | 2.08 | 0.69 | 0.78 | 0.84 | 3.25 | |
| Current ratio | 2.32 | 1.48 | 1.65 | 1.71 | 1.82 | |
| Interest coverage | 40.13 | 67.36 | 34.5 | 22.96 | 6.05 | |
| Income quality | 1.24 | 0.96 | 0.67 | 0.56 | 1.09 | |
| Dividend Yield | 0 | 0 | 0.04 | 0 | 0 | |
| Payout ratio | 0 | 0 | 1.14 | 0 | 0 | |
| Sales general and administrative to revenue | 0.15 | 0.5 | 0.48 | 0.52 | 0.13 | |
| Research and developement to revenue | 0.02 | 0.04 | 0.03 | 0.03 | 0.06 | |
| Intangibles to total assets | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Capex to operating cash flow | -0.22 | -2.13 | 0.23 | -1.14 | -0.4 | |
| Capex to revenue | -0.03 | -0.2 | 0.02 | -0.04 | -0.04 | |
| Capex to depreciation | -1.21 | -5.75 | 0.65 | -1.24 | -1.26 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 11.78K | 10.22K | 12.51K | 8.88K | 10.71K | |
| ROIC | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Graham Net | -343.39 | -810.96 | -473.66 | -347.66 | -314.67 | |
| Working capital | 58.82B | 32.38B | 39.97B | 43.65B | 46.29B | |
| Tangible asset value | 256.41B | 248.93B | 257.19B | 259.9B | 263.58B | |
| Net current asset value | 25.96B | 19.58B | 27.28B | 30.65B | 32.02B | |
| Invested capital | 0.13 | 0.1 | 0.11 | 0.11 | 0.1 | |
| Average receivables | 45.08B | 44.54B | 45.07B | 46.65B | 46.98B | |
| Average payables | 7.24B | 8.65B | 8.83B | 8.51B | 7.53B | |
| Average inventory | 40.19B | 43.07B | 46.37B | 48.64B | 48.8B | |
| Days sales outstanding | 73.42 | 74.23 | 71.42 | 77.35 | 72.41 | |
| Days payables outstanding | 35.8 | 41.33 | 35.84 | 36.38 | 26.79 | |
| Days of inventory on hand | 183.83 | 200.05 | 204.52 | 208.11 | 200.9 | |
| Receivables turnover | 1.23 | 1.21 | 1.26 | 1.16 | 1.24 | |
| Payables turnover | 2.51 | 2.18 | 2.51 | 2.47 | 3.36 | |
| Inventory turnover | 0.49 | 0.45 | 0.44 | 0.43 | 0.45 | |
| ROE | 0.03 | 0.02 | 0.03 | 0.01 | 0.02 | |
| Capex per share | -109.52 | -626.37 | 70.19 | -141.57 | -136.78 |
293480.KS Frequently Asked Questions
What is Hana Pharm Co., Ltd. stock symbol ?
Hana Pharm Co., Ltd. is a KR stock and trading under the symbol 293480.KS
What is Hana Pharm Co., Ltd. stock quote today ?
Hana Pharm Co., Ltd. stock price is $13240 today.
Is Hana Pharm Co., Ltd. stock public?
Yes, Hana Pharm Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 21.84K
- Market Capitalization 229.39B
- CEO Taehong Choi
- Headquarters Seoul,KR
- IPO Date 2018-10-02
-
Website
https://www.hanaph.co.kr 
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1958 and is headquartered in Seoul, South Korea.
